Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease

Gut

Volumn 61, Issue 2, 2012, Pages 235-240

  Van Schaik, Fiona D M ^a   Van Oijen, Martijn G H ^a   Smeets, Hugo M ^a,b   Van Der Heijden, Geert J M G ^a   Siersema, Peter D ^a   Oldenburg, Bas ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Agis Health Insurance   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; MESALAZINE; OLSALAZINE; SALAZOSULFAPYRIDINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER PREVENTION; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; CROHN DISEASE; CYTOPATHOLOGY; DISEASE ASSOCIATION; DISEASE REGISTRY; DRUG EFFICACY; ENTERITIS; FEMALE; FOLLOW UP; GASTROINTESTINAL DYSPLASIA; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL; TREATMENT DURATION; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZATHIOPRINE; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MESALAMINE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK;

EID: 84855206195     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2011.237412     Document Type: Article

References (32)

1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35. (Pubitemid 32234798)
2. Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91:854-62. (Pubitemid 32173312)
3. Gillen CD, Walmsley RS, Prior P, et al. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 1994;35:1590-2. (Pubitemid 24339258)
4. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004;287:G7-17.
5. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005;100:1345-53. (Pubitemid 40904360)
6. Jess T, Loftus EV Jr, Velayos FS, et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested caseecontrol study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol 2007;102:829-36. (Pubitemid 46496613)
7. Terdiman JP, Steinbuch M, Blumentals WA, et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 2007;13:367-71. (Pubitemid 46668239)
8. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-9. (Pubitemid 38182302)
9. van Staa TP, Card T, Logan RF, et al. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005;54:1573-8. (Pubitemid 41531774)
10. Kauffman HM, Cherikh WS, McBride MA, et al. Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int 2006;19:607-20.
11. Marcen R, Pascual J, Tato AM, et al. Influence of immunosuppression on the prevalence of cancer after kidney transplantation. Transplant Proc 2003;35:1714-16. (Pubitemid 37093684)
12. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6- mercaptopurine. Gut 2005;54:1121-5. (Pubitemid 41025906)
13. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25.
14. Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010;8:268-74.
15. Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994;107:934-44. (Pubitemid 24294554)
16. Fraser AG, Orchard TR, Robinson EM, et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002;16:1225-32.
17. Lashner BA, Provencher KS, Seidner DL, et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997;112:29-32. (Pubitemid 27008982)
18. Matula S, Croog V, Itzkowitz S, et al. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol 2005;3:1015-21. (Pubitemid 41415750)
19. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95. (Pubitemid 32096335)
20. Smeets HM, de Wit NJ, Hoes AW. Routine health insurance data for scientific research: potential and limitations of the Agis Health Database. J Clin Epidemiol 2011;64:424-30.
21. Tsiachristas A, Hipple-Walters B, Lemmens KM, et al. Towards integrated care for chronic conditions: Dutch policy developments to overcome the (financial) barriers. Health Policy 2011;101:122-32.
22. Enthoven AC, van de Ven WP. Going Dutchdmanaged-competition health insurance in the Netherlands. N Engl J Med 2007;357:2421-3. (Pubitemid 350272779)
23. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a caseecontrol study. Aliment Pharmacol Ther 2000;14:145-53. (Pubitemid 30088290)
24. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based caseecontrol study. Am J Gastroenterol 2010;105:1604-9.
25. Disanti W, Rajapakse RO, Korelitz BI, et al. Incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6-mercaptopurine for inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:1025-9. (Pubitemid 44118838)
26. Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. EpsteineBarr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002;122:72-7. (Pubitemid 34049196)
27. Sandborn WJ, Sutherland LR, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000;2: CD000545.
28. Person DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995;123:132-42.
29. Farraye FA, Odze RD, Eaden J, et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010;138:746-74.
30. Bernstein CN, Blanchard JF, Metge C, et al. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003;98:2784-8. (Pubitemid 38020124)
31. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharamacol Ther 2006;23:577-85.
32. Lutgens MW, van der Heijden GJ, Vleggaar FP, et al. A comprehensive metaanalysis of the risk of colorectal cancer in ulcerative colitis and Crohn's disease. Gastroenterology 2008;134(Suppl 1):A-33-A-34.